Myonecrosis after elective percutaneous coronary intervention: Effect of clopidogrel-statin interaction

Journal of Invasive Cardiology

Volumn 17, Issue 11, 2005, Pages 589-593

  Gulec, Sadi ^a   Ozdol, Cagdas ^a   Rahimov, Uzeyir ^a   Atmaca, Yusuf ^a   Kumbasar, Deniz ^a   Erol, Cetin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; TROPONIN T;

ARTICLE; CARDIAC PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; ELECTIVE SURGERY; ENZYME METABOLISM; EX VIVO STUDY; FEMALE; HEART MUSCLE INJURY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; RISK ASSESSMENT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CREATINE KINASE, MB FORM; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEART; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TROPONIN T;

EID: 33645976924     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
2. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1314-1322.
3. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-1744.
4. Nageh T, Sherwood RA, Thomas MR. Prognostic implications of cardiac marker elevation after percutaneous coronary intervention. Circulation 2002;105:e73.
5. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.
6. Chan AW, Bhatt DL, Chew DP, et al Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756.
7. Herrmann J, Lerman A, Baumgart D, et al. Pre-procedural statin medication reduces the extent of peri-procedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
8. Aronow HD, Quinn MJ, Gurm HS, et al. Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipidlowering therapy (Abstr.). J Am Coll Cardiol 2002;39:32A.
9. Bertrand ME, Ruppert HJ, Peterson J, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-629.
10. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drugdrug interaction. Circulation 2003;107:32-37.
11. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-59.
12. Horsmans Y. Differential metabolism of statins: Importance in drug-drug interactions. Eur Heart J Supplements 1999;1 (Suppl T):T7-T12.
13. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
14. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
15. Garbarz E, Lung B, Lefevre G, et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 1999;84:515-518.
16. Bonz AW, Lengenfelder B, Strormann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pre-treatment with aspirin and clopidogrel (TOPSTAR Trial). J Am Coll Cardiol 2002;40:662-668.
17. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevation and the diagnosis of non-Q wave myocardial infarction associated with coronary angiography. J Am Coll Cardiol 1991;17:621-626.
18. Liu MW, Douglas JS Jr, Lembo NJ, King SB III. Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. Am J Cardiol 1993;72:514-517.
19. Atmaca Y, Gulec S, Ertas F, et al. The prevention of minor myocardial injury with ticlopidine pretreatment in patients undergoing elective coronary stenting. Int J Cardiol 2003;87:151-157.
20. Atmaca Y, Dandachi R, Gulec S, et al. Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting. Int J Cardiol 2003;87:143-149.
21. The Epic Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
22. Van de Werf F. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa blockade during coronary interventions - Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996;17:325-326.
23. Weinbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-288.
24. Saw J, Steinhubl SR, Berger P, et al. Lack of adverse clopidogrelatorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-924.
25. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-1338.
26. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - A flow cytometry study. Eur Heart J 2003;24:1744-1749.